MEBO Director Prof Irene Gabashvili writes a final post on the MEBO-Ubiome Study
Irene has long been a helper to MEBO, and oversaw the Ubiome - MEBO study.
Unfortunately as most of you know, Ubiome went out of business (due to getting involved in the USA Health System market).
But MEBO managed to get what raw data there was from the study (at the last moment) for Irene to analyze.
Irene has her own company, Aurametrix.
In her latest Aurametrix blog post, she writes her final thoughts on the MEBO - Ubiome data.
In short, it is possible to develop a diagnostic test for MEBO - machine learning models can predict flareups based on uBiome data (if I randomly choose test set and validation sets) - but this prediction is based on at least ~200 bacteria, and dependence is complex, non-linear.
Developing a FDA QSR compliant diagnostic product would be expensive and not worth it.
Final Aurametrix blog post on MEBO -Ubiome study
![[Facebook Share]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vtJ3urCNcEhyLTIYVkykIgNLTozjEtiaUEBvxcy7UeolUfJd2X-WIs1l89AFbiXMbFwuDUvCw3s4ftp-S22y0J-DFO92U=s0-d){kind=small}
UK 
Spain 
1 comments:
Is this a new research for tmau?
https://www.healtheuropa.eu/fish-odour-syndrome-dermetel-aims-to-give-patients-a-breath-of-fresh-air/96357/